Genprex Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Genprex ha un patrimonio netto totale di $1.7M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $3.9M e $2.2M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$1.49m
Patrimonio netto	US$1.66m
Totale passività	US$2.24m
Totale attività	US$3.91m

Aggiornamenti recenti sulla salute finanziaria

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16

Recent updates

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { GNPX di $1.9M ) non coprono le sue passività a breve termine ( $2.2M ).

Passività a lungo termine: GNPX non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: GNPX è esente da debiti.

Riduzione del debito: GNPX non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: GNPX ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: GNPX ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 19.2 % ogni anno

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/01/12 04:22
Prezzo dell'azione a fine giornata	2025/01/10 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Genprex, Inc. è coperta da 1 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners

Genprex Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. announced delayed 10-Q filing

Recent updates

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Price target increased to US$6.50

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex: Limited Clinical Data To Justify Risk

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$8.25

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex' stock jumps after corporate update

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex completes manufacturing scale-up of lung cancer therapy

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer